Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cocrystal Pharma ( (COCP) ) has issued an update.
On April 2, 2026, Cocrystal Pharma announced that the U.S. Food and Drug Administration granted Fast Track designation to CDI-988, its oral, direct-acting protease inhibitor and the first known oral antiviral candidate being developed for both treatment and prophylaxis of norovirus infection. The Fast Track status is designed to speed development and review of therapies for serious conditions with unmet needs, providing Cocrystal with closer FDA interaction, eligibility for rolling review of a future New Drug Application and the potential for expedited regulatory timelines.
CDI-988 targets a highly conserved region of noroviruses, coronaviruses and other 3CL viral proteases, and is currently being evaluated in an ongoing Phase 1b randomized, double-blind, placebo-controlled norovirus challenge study at Emory University School of Medicine in up to 40 healthy adults, with endpoints including symptom reduction, viral shedding, disease severity, safety and pharmacokinetics. Given norovirus’s massive global health and economic burden, Cocrystal’s new regulatory milestone underscores its ambition to deliver a first-in-class therapeutic and preventive option, potentially strengthening its position in the antiviral market while highlighting the broader promise of its structure-based drug discovery platform for pan-viral antivirals.
The most recent analyst rating on (COCP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.
The score is primarily constrained by weak financial performance—no meaningful revenue, ongoing losses, negative cash flow, and significant equity erosion—despite some 2025 improvement and low leverage. Technicals remain soft with the stock below key longer-term moving averages. Corporate events are mixed, with encouraging early-stage clinical milestones partially offset by negative leadership/govemance news, while valuation is difficult to support due to negative earnings and no dividend data.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics that target the replication processes of noroviruses, influenza viruses, coronaviruses including SARS-CoV-2, and rhinoviruses. Using a structure-based drug discovery platform and expertise rooted in Nobel Prize-winning science, the company designs next-generation, broad-spectrum antivirals that bind conserved viral enzyme regions to preserve potency against mutating strains while aiming to minimize off-target effects.
This technology-driven approach is intended to streamline antiviral candidate identification and optimization, supporting rapid advancement of compounds with strong resistance and safety profiles. Cocrystal’s pipeline includes oral, direct-acting antivirals such as CDI-988, and the company’s work positions it within the competitive antiviral therapeutics market, addressing substantial unmet medical needs in both developed and developing countries.
Average Trading Volume: 62,513
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.06M
Find detailed analytics on COCP stock on TipRanks’ Stock Analysis page.